Volume | 22,049 |
|
|||||
News | - | ||||||
Day High | 2.74 | Low High |
|||||
Day Low | 2.4501 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Genprex Inc | GNPX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.59 | 2.4501 | 2.74 | 2.614 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
158 | 22,049 | $ 2.61 | $ 57,441 | - | 2.09 - 42.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:19:42 | 50 | $ 2.66 | USD |
Genprex Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.8M | 1.49M | - | 0 | -30.86M | -20.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Genprex News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.31 | 2.74 | 2.21 | 2.49 | 28,981 | 0.22 | 9.52% |
1 Month | 3.03 | 3.23 | 2.09 | 2.56 | 29,623 | -0.50 | -16.50% |
3 Months | 4.65 | 5.41 | 2.09 | 3.65 | 52,198 | -2.12 | -45.59% |
6 Months | 13.60 | 14.40 | 2.09 | 8.66 | 291,886 | -11.07 | -81.40% |
1 Year | 32.40 | 42.40 | 2.09 | 20.73 | 407,553 | -29.87 | -92.19% |
3 Years | 138.40 | 162.80 | 2.09 | 97.48 | 855,079 | -135.87 | -98.17% |
5 Years | 71.60 | 308.80 | 2.09 | 117.66 | 1,275,461 | -69.07 | -96.47% |
Genprex Description
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. |